116094-23-6

White or almost white powder

recombinant, biosynthetic, fast-acting insulin analogue helping control the blood sugar level of those with type 1 and type 2 diabetes mellitus. It has a single amino acid substitution at position B28 where proline is replaced with aspartic acid. This sub

Insulin Aspart[116094-23-6] is a rapid-acting insulin analog produced by recombinant DNA technology. It differs structurally from human insulin in that aspartic acid replaces the original proline at position 28 of the B chain.This modification allows for improved postprandial glucose control in diabetic patients. The USP biologics proteins category provides critical standards and reference materials necessary for the development and manufacturing of therapeutic proteins. These proteins, which can be naturally derived or genetically engineered, are essential in treating various diseases and conditions, ensuring that they meet quality, safety, and efficacy standards.

Insulin aspart is produced using recombinant DNA technology in yeast. It is engineered by replacing proline at position B28 of the human insulin amino acid chain with aspartic acid. This substitution introduces a negative charge that creates electrostatic repulsion, thereby preventing insulin monomers or dimers from aggregating. This structural modification weakens the intermolecular interactions between insulin molecules in solution, reduces molecular aggregation, and promotes rapid dissociation into monomers.

Insulin aspart has the same mechanism of action as endogenous human insulin. It binds to insulin receptors in muscle and adipose tissue, thereby enhancing glucose uptake and inhibiting hepatic glucose release.